Progesterone is a C21 steroid which is synthesized from both tissue and circulating cholesterol. Cholesterol is transformed to Progesterone which is then converted via a combined dehydrogenase and isomerase to progesterone. The principle production sites are the adrenals and ovaries and the placenta during pregnancy. The majority of this steroid is metabolized in the liver to pregnanediol and conjugated as a glucuronide prior to excretion by the kidneys. Progesterone exhibits a wide variety of end organ effects. The primary role of progesterone is exhibited by the reproductive organs. In males, progesterone is a necessary intermediate for the production of corticosteroids and androgens. In females, progesterone remains relatively constant throughout the follicular phase of the menstrual cycle. The concentration then increases rapidly following ovulation and remains elevated for 4-6 days and decreases to the initial level 24 hours before the onset of menstruation. In pregnancy, placental progesterone production rises steadily to levels of 10 to 20 times those of the luteal phase peak. Progesterone measurements are thus performed to determine ovulation as well as to characterize luteal phase defects. Monitoring of progesterone therapy and early stage pregnancy evaluations comprise the remaining uses of progesterone assays. Progesterone EIA kits are designed for the measurement of total progesterone in human serum or plasma.

Catalog number SDL7973
Product type ELISA
Quantity 96 Tests (12×8 breakable strip wells)
Standard range 2.5-40 ng/ml
Analytical Sensitivity 2.5 ng/ml
Sample volume 10 µl/well
Species Human

The SDi Progesterone ELISA kit is used for the quantitative measurement of Progesterone in human serum or plasma.

The SDi Progesterone kit is a solid phase competitive ELISA. The samples and Progesterone enzyme conjugate are added to the wells coated with anti-Progesterone monoclonal antibody. Progesterone in the patient’s sample competes with a Progesterone enzyme conjugate for binding sites. Unbound Progesterone and Progesterone enzyme conjugate is washed off by washing buffer. Upon the addition of the substrate, the intensity of color is inversely proportional to the concentration of Progesterone in the samples. A standard curve is prepared relating color intensity to the concentration of the Progesterone

Storage and Stability
Product should be stored at 2-8 °C. Product is stable for 24 months from the date of manufacturing.

For research use only. Not for use in diagnostic procedures.

1. Radwanska, E., Frankenberg, J., and Allen, E., Plasma progesterone levels in normal and abnormal early human pregnancy. Fertility and Sterility, 1978; 30, 398-402.
2. Autrere,M.B., and Benson, H., Progesterone: An overview and recent advances, J. Par. Sci., 1976; 65: 783-800.
3. March, C.M., Goebelsmann, U., Nakamura, R.M., and Mishell, D.R. Jr., Roles of estradiol and progesterone in eliciting the midcycle luteinizing hormone and follicle-stimulating hormone surges, J. Clin. Endo. Metab., 1979; 49, 507-513.
4. Ross, G.T., Vande Wiele, R.L., and Frantz, A.G., The Ovaries and the breasts. In: Williams, R.H., ed., Textbook of Endocrinology. Saunders Company, Philadelphia; 1981: 355-411.
5. Chattoraj, S.C., Endocrine function. In: Tietz, N.W., ed., Fundamentals of Clinical Chemistry. Saunders Company, Philadelphia; 1976: 699-823.
6. Shepard, M.K., and Senturia, Y.D., Comparison of serum progesterone and endometrial biopsy for confirmation of ovulation and evaluation of luteal function. Fertility and Sterility, 1977; 28: 541-548.
7. Johansson, E.D.B., and Jonasson, L.-E., Progesterone levels in amniotic fluid and plasma from women: I. Levels during normal pregnancy. Acta Obstet. Gynec. Scand., 1971; 50: 339-343.
8. USA Center for Disease Control/National Institute of Health Manual, “Biosafety in Microbiological and Biomedical Laboratories”” 1984.
9. Tietz, N.W. ed., Clinical Guide to Laboratory Tests, 3rd Edition, W.B. Saunders, Co., Philadelphia, 1995: 509-512.
10. ICN Guide to Endocrine Testing. Diagnostic Division, ICN Biomedicals, Inc. pp. 2:20-27.